Fundraising FoxOrbiMed — 2022 Investments
8 investments dated 2022 · listed companies and verified rows first · show all
Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.
BiotechHealthtechMedical Devices
Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)
Co-investorsAtlas VentureRA CapitalViking Global
Dario provides digital tools and support to help people manage chronic conditions such as diabetes between provider visits.
BiotechDigital HealthHealthtechMental HealthWellness & FitnessNew York, US
Oren Fuerst, PhD(Director)Erez Raphael(Chief Executive Officer)inZvi Ben David(Chief Financial Officer, Treasurer, and Secretary)inSteven Nelson(Chief Commercial Officer)inGadi Levin(Executive Officer, Director)in
BoardAdam K. Stern(Director)
Co-investorsAgate Medical Investments LPLeo Capital VenturesPitango
Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.
AI & Machine LearningBiotechDeep Tech
Clarissa Desjardins(Founder)in
Co-investorsAlexandriaDIMENSIONAngelini VenturesBDC Thrive Venture Fund for WomenLumira VenturesAmplitude Venture Capital+1 more
MDClone provides a healthcare data platform that uses synthetic data to support clinical research and care-improvement initiatives, used by health systems such as Intermountain for programs targeting chronic conditions like kidney disease, diabetes, and cardiovascular disease.
AI & Machine LearningData & InfrastructureDigital HealthHealthtech
Ziv Ofek(Co-Founder and President)inBruno Lempernesse(Chief Executive Officer)inAaron Galaznik(Chief Medical Officer)inAlmog Ohayon(Chief Product and Technology Officer)in
Co-investorsaMoonLightspeed Venture PartnersWarburg PincusDeclaration PartnersViola Ventures
HealthtechCarlsbad, US
Christoph Scharf(Director)inRandy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)inVince Burgess(Director)inJohn Dahldorf(Executive Officer)
BoardAditya Puri(Director)
Board seatDavid Bonita· per SEC Form D
Co-investorsAdvent Life SciencesXeraya CapitalDeerfield Management CompanyFormation GroupGE VenturesIndex Ventures
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHBM Healthcare InvestmentsHBM PartnersHongShan Capital Group+4 more
.png)
LifeCell Diagnostics provides preventive health checkups and lab tests, including full-body checks, women's wellness packages, allergy panels, and organ-specific tests, with at-home sample collection and digital report delivery.
BiotechConsumerDigital HealthHealthtechMedical DevicesChennai, IN
Abhaya Kumar Jain(Chairman)Mayur Abhaya Jain(Managing Director)Sumanth Sarangapani(CEO)in
MDxHealth is a commercial-stage precision diagnostics company offering molecular diagnostic tests to guide the diagnosis and treatment of prostate cancer and other urologic diseases.
BiotechDigital HealthHealthtechMedical DevicesHerstal, US
John Bellano(Chief Commercial Officer of the Issuer.)inRon Kalfus(Chief Financial Officer of the Issuer.)inJoseph Sollee(Executive Officer)Wim Van Criekinge(Chief Scientific Officer)inMichael McGarrity(Chief Executive Officer & Executive Director)Christian Sollee(Executive Vice President of Corporate Development and General Counsel)
Co-investorsAndera Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.